汤朝晖

男， 中国科学院长春应用化学研究所， 教授/研究员/教授级高工或同等级别

学习/工作经历

1995-9至1999-7, 湘潭大学, 应用化学, 学士
1999-9至2005-3, 中国科学院长春应用化学研究所, 高分子化学与物理, 博士
2005-2至2006-7, Imperial College London, 博士后, 
2007-3至2008-12, State University of New York at Stony Brook, 博士后,
2009-4至2014-12, 中国科学院长春应用化学研究所, 副研究员
2014-12至今, 中国科学院长春应用化学研究所, 研究员

研究领域和兴趣

高分子化学；高分子药物载体；药物靶向递送

主要业绩

主要从事高分子载体抗肿瘤纳米药物研究。针对传统抗肿瘤纳米药物存在的渗透和靶向能力低等问题，提出了肿瘤“边缘与中心”协同治疗、“凝血靶向”和“链式自放大靶向”等的纳米药物研究新思路，发现纳米技术可以显著提高血管阻断剂的肿瘤血管靶向性和抑瘤能力，构建了高分子血管阻断剂，把纳米药物的瘤内渗透能力低从“缺点”转变为“优势”。在Advanced Materials、Advanced Science、Progress in polymer science、Nano Letters、Biomaterials、Chemical Science、Journal of controlled release等知名期刊发表学术论文120余篇，SCI他引8000余次，申请中国发明专利40余项，其中已授权专利30 余项，申请PCT专利2项，获授权美国专利1项。2011年首批入选中国科学院青年创新促进会；2015年首批入选中国科学院青年创新促进会优秀会员；2019年获得吉林省科学技术一等奖（排名第二）；2020年获得国家杰出青年科学基金资助。主持科技部国家重点研发计划项目1项、科技部国家重点研发计划国际合作项目1项、国家自然科学基金面上项目4项、国家自然科学青年基金1项，主持中国科学院青年创新促进会“会员”和“优秀会员”项目各1项，主持吉林省科技厅重点项目1项；参与重大新药创制国家科技重大专项3项。

代表成果

(1) Xu, H.; Zheng, M.; Ye, D.; An, J.; Liu, Z.; Tang, Z.; Chen, X. Ultrasound-Triggered Activation of p-Azidobenzyloxycarbonyl-Based Prodrugs via Radical-Mediated Cascade Elimination. Journal of the American Chemical Society 2025, 147 (24), 20667-20679.
(2) Sun, J.; Yao, H.; Yang, C.; Xue, F.; Ren, X.; Cui, L.; Liu, Z.; Tang, Z.; Chen, X. Ultrasound-induced single-electron reduction of azide groups in aromatic prodrugs. National Science Review 2025, 12 (6), nwaf140.
(3) Liu, L.; Huang, Z.; Zhu, Z.; Sun, A.; Zhao, J.; Xu, Y.; Song, W.; Tang, Z.; Chen, X. Dynamic Size-Change Nanovaccine for Enhancing Lymph Node Deep Penetration and Eliciting Robust Antitumor Immune Responses. Adv. Mater. 2025, 37 (39), e2504909.
(4) Chu, H.; Shan, Y.; Liu, Z.; Sun, M.; Zhao, W.; Xie, X.; Wang, K.; Yang, C.; Fang, X.; Shen, N.; et al. Rejuvenation of Tumor-Specific T Cells via Ultrahigh DAR Antibody-Polymeric Imidazoquinoline Complexes: Coordinated Targeting of PDL1 and Efficient TLR7/8 Activation in Intratumoral Dendritic Cells. Adv. Mater. 2025, 37 (17), e2412974.
(5) Xu, Y.; Lv, J.; Liu, F.; Wang, J.; Liu, Y.; Kong, C.; Li, Y.; Shen, N.; Gu, Z.; Tang, Z. Tumor Microenvironment Remodeling‐Mediated Sequential Drug Delivery Potentiates Treatment Efficacy. Adv. Mater. 2024, 36 (23), e2312493.
(6) Xu, Y.; Lv, J.; Kong, C.; Liu, Y.; Wang, K.; Tang, Z.; Chen, X. Introducing urea into the tirapazamine derivatives to enhance anti-cancer therapy. National Science Review 2024, 11 (4), nwae038.
(7) Kong, C.; Li, Y.; Xu, Y.; Luo, C.; Shen, N.; Tang, Z.; Chen, X. Ultrasound Irradiation-Induced Superoxide Anion Radical Mediates the Reduction of Tetravalent Platinum Prodrug for Anti-tumor Therapy. CCS Chemistry 2024, 7 (4), 1142-1156.
(8) Sun, J.; Liu, Z.; Yao, H.; Zhang, H.; Zheng, M.; Shen, N.; Cheng, J.; Tang, Z.; Chen, X. Azide-Masked Resiquimod Activated by Hypoxia for Selective Tumor Therapy. Adv. Mater. 2023, e2207733.
(9) Liu, Z.; Zhang, H.; Sun, J.; Zheng, M.; Cui, L.; Zhang, Y.; Cheng, J.; Tang, Z.; Chen, X. Organic‐Solvent‐Free “Lego‐Like” Modular Preparation of Fab‐Nondestructive Antibody‐Drug Conjugates with Ultrahigh Drug‐to‐Antibody Ratio. Adv. Mater. 2023, 35 (46), e2300377.
(10) Zhao, J.; Xu, Y.; Ma, S.; Wang, Y.; Huang, Z.; Qu, H.; Yao, H.; Zhang, Y.; Wu, G.; Huang, L.; et al. A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy. Adv. Mater. 2022, 34 (10), e2109254.
(11) Xu, Y.; Lv, J.; Shen, N.; Tang, Z.; Chen, X. A self-activating nanoized vascular disrupting agent for selective anti-tumor therapy. Biomaterials 2022, 288, 121736.
(12) Wang, Y.; Shen, N.; Wang, Y.; Zhang, Y.; Tang, Z.; Chen, X. Self-Amplifying Nanotherapeutic Drugs Homing to Tumors in a Manner of Chain Reaction. Adv. Mater. 2021, 33 (7), e2002094.
(13) Liu, Z.; Yu, H.; Shen, N.; Tang, Z.; Chen, X. A ROS-Stimulus-Responsive Nanocarrier Loading with Guanidine-Modified Hydroxycamptothecin Prodrug for Enhanced Anti-Tumor Efficacy. CCS Chemistry 2020, 2 (5), 305-316.
(14) Yang, S.; Tang, Z.; Hu, C.; Zhang, D.; Shen, N.; Yu, H.; Chen, X. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors. Adv. Mater. 2019, 31 (11), e1805955.
(15) Jiang, J.; Shen, N.; Ci, T.; Tang, Z.; Gu, Z.; Li, G.; Chen, X. Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug. Adv. Mater. 2019, 31 (44), e1904278.

*以上信息由高级会员个人更新和维护。